News & Events

Researchers around Martin Fussenegger from the Biotechnology Lab have developed a new gene switch that can be activated using a commercially available nitroglycerine patch applied to the skin. One day, researchers want to use switches of this kind to trigger cell therapies for various metabolic diseases.

On 29 January, BioVersys launches its Initial Public Offering on the SIX Swiss Exchange. “Today marks the first step of us engaging with the public so that we may make the next clinical phase of developing BV100 and alpibectir and their eventual approval a reality,” says Marc Gitzinger, CEO and Co-Founder of BioVersys. BV100 and alpibectir are novel antimicrobial drug candidates targeting the most drug-resistant bacterial pathogens Acinetobacter baumannii and Mycobacterium tuberculosis.

Last year was our first year in the new building on campus Schällemätteli in Basel: we celebrated the official opening of the BSS-building in May, and along the year many awards, prizes and scientific milestones; we welcomed five new faculty members; we became the leading partner in the new academic alliance for the Botnar Institute of Immune Engineering; and we saw great progress in the Next-gen Bioengineers and ETM partnerships. See what was going on at D-​BSSE in 2024!

A study in Nature Physics on the early stages of bladder cancer shows the importance of mechanical changes in tumour tissue during growth. The study was led by the Computational Biology group of Dagmar Iber in collaboration with Lukas Bubendorf’s pathology lab at the University Hospital Basel and the D-BSSE group of Biophysics.